Harrow Health, Inc. (HROW)
$28.24-2.99%Close
SELLCRISIS · day 23
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $1.1B
- Beta
- 0.24
- P/E (TTM)
- -28.45
- Short % float
- 27.45%
- Days to cover
- 12.4
- SI change
- +3.7%
- 1W
- -6.95%
- 1M
- -17.11%
- vs SPY 1W
- -7.37%
- vs SPY 1M
- -19.17%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 53
- VALUE
- 9
- GROWTH
- 46
- GARP
- 81
- TYPE
- Growth Compounder
Composite of Value · Growth · GARP
ROIC-62.3%
REV YoY-
ROE-103.9%
EPS YoY-
ROA-8.9%
GROSS73
OP2
NET-14
[VALUATION]
P/E TTM-28.45
P/E FWD14.54
SECTOR PE20.34
INDUSTRY PE19.31
P/B69.39
P/FCF-
EV/EBITDA113.48
EV/EBIT-
PEG0.30
FCF YIELD-
RISK
INT COV-
D/E1978.58
ALTMAN Z-
CURR RATIO2.24
ND/EBITDA-
BETA0.24
Company news
FAQ
- What is LOPJLB’s current signal on HROW?
- LOPJLB’s latest quantitative signal on Harrow Health, Inc. (HROW) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is HROW in?
- Harrow Health, Inc. (HROW) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Harrow Health, Inc. (HROW) do?
- Harrow Health, Inc. operates as a healthcare enterprise with a specialized focus on ophthalmic solutions. The company's portfolio includes ImprimisRx, a business dedicated to ophthalmology outsourcing and pharmaceutical compounding, as well as DEXYCU, a product utilized for managing post-operative inflammation. Beyond its direct offerings, Harrow Health maintains equity investments in several p…